Cite
HARVARD Citation
Baramidze, A. et al. (n.d.). 122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I. Immuno-oncology technology. p. . [Online].